biopharmadive.com· Jonathan Gardner·· 4 hours agoPickScore90
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
In brief
In a late-stage trial in post-surgical melanoma, Moderna and Merck's intismeran autogene combined with Keytruda reduced the relative risk of disease recurrence or death by 42% compared with Keytruda alone, with a median follow-up of 24.6 months.
Why it matters
Trial provides a 42% relative risk reduction in recurrence or death and safety data, allowing direct comparison with Keytruda alone and investor expectations.
Source: biopharmadive.com · biopharmadive.com